Introduction
Tau propagation refers to the intercellular spread of pathological tau protein aggregates in the brain, a process that underlies the progression of Alzheimer’s disease (AD) and related tauopathies including Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), and Primary Age-Related Tauopathy (PART)1Tau propagation models and therapeutic implications (2024)Open reference2Tau oligomers and propagation in neurodegenerative diseases (2023)Open reference. The propagation of tau follows a characteristic pattern that closely correlates with clinical symptoms and disease staging, beginning in the entorhinal cortex and spreading through connected neural networks to the hippocampus, limbic system, and eventually the neocortex3Braak & Braak, Neuropathological staging of Alzheimer-related changes (1991)Open reference4In vivo tau PET imaging in Alzheimer's disease (2024)Open reference. Understanding the mechanisms of tau propagation has become central to developing disease-modifying therapies for Alzheimer’s disease, as tau pathology shows stronger correlation with cognitive decline than amyloid-beta deposition alone5Tau and amyloid as predictors of cognitive decline (2023)Open reference6Relationship between tau pathology and cognition in Alzheimer's disease (2024)Open reference.
The concept of tau propagation emerged from observations that the spatial distribution of neurofibrillary tangles (NFTs) follows a predictable pattern that correlates with clinical disease progression7Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade (2010)Open reference. This staged pattern of tau pathology suggested that the disease process spreads through connected brain regions rather than arising independently in each area. Subsequent research demonstrated that pathological tau can transfer between neurons, propagate along neural circuits, and template the misfolding of endogenous tau in recipient cells—a process analogous to prion diseases8Propagation of tau aggregation in a mouse model (2009)Open reference9Cell-to-cell transmission of tau aggregates (2013)Open reference. This mechanistic understanding has profound implications for therapeutic intervention, as blocking tau propagation could potentially halt disease progression even after amyloid pathology is established.
Tau Protein Biology
Normal Tau Function
Tau is a microtubule-associated protein encoded by the MAPT (Microtubule-Associated Protein Tau) gene on chromosome 17q21, primarily expressed in neurons where it plays essential roles in axonal transport, synaptic function, and neuronal polarity10Tau physiology and pathology (2022)Open reference2Tau oligomers and propagation in neurodegenerative diseases (2023)Open reference0. The tau protein exists in six isoforms in the human brain, generated by alternative splicing of exons 2, 3, and 10, which differ in the number of microtubule-binding repeat domains (three or four repeats; 3R or 4R tau)2Tau oligomers and propagation in neurodegenerative diseases (2023)Open reference1. These isoforms have distinct functional properties, with 4R tau isoforms having higher microtubule-binding affinity than 3R isoforms, and the balance between 3R and 4R tau being critical for normal neuronal function2Tau oligomers and propagation in neurodegenerative diseases (2023)Open reference2.
In its normal state, tau promotes microtubule assembly and stability through its repeat domains, which bind to microtubules and regulate their polymerization and dynamic instability2Tau oligomers and propagation in neurodegenerative diseases (2023)Open reference3. The N-terminal projection domain projects away from the microtubule surface and interacts with other cellular components, including the plasma membrane and organelles2Tau oligomers and propagation in neurodegenerative diseases (2023)Open reference4. This dual functionality allows tau to serve as a linker between microtubules and cellular organelles, facilitating vesicular transport along axons and dendrites. Additionally, tau has been implicated in regulating neuronal signaling pathways, including those involving GSK-3 beta and other kinases that phosphorylate tau2Tau oligomers and propagation in neurodegenerative diseases (2023)Open reference5.
Tau Phosphorylation and Post-Translational Modifications
The functional state of tau is highly regulated by post-translational modifications, with phosphorylation being the most extensively studied2Tau oligomers and propagation in neurodegenerative diseases (2023)Open reference6. In the normal brain, tau exists in a relatively dephosphorylated state, with only 2-3 moles of phosphate per mole of tau. In disease states, tau becomes hyperphosphorylated, containing 5-9 moles of phosphate per mole of tau2Tau oligomers and propagation in neurodegenerative diseases (2023)Open reference7. This hyperphosphorylation reduces tau’s affinity for microtubules, leading to microtubule destabilization and impaired axonal transport2Tau oligomers and propagation in neurodegenerative diseases (2023)Open reference8.
Multiple kinases phosphorylate tau in vitro and in vivo, including GSK-3 beta, CDK5 (Cyclin-Dependent Kinase 5), MAP kinases (ERK1/2, p38), and casein kinases2Tau oligomers and propagation in neurodegenerative diseases (2023)Open reference9. GSK-3 beta and CDK5 are considered the primary kinases responsible for pathological tau phosphorylation in AD brain, as both are activated by neurotoxic stimuli and can phosphorylate tau at multiple AD-relevant sites3Braak & Braak, Neuropathological staging of Alzheimer-related changes (1991)Open reference03Braak & Braak, Neuropathological staging of Alzheimer-related changes (1991)Open reference1. The balance between kinases and phosphatases (particularly PP2A) determines the phosphorylation state of tau, and dysregulation of this balance contributes to pathological hyperphosphorylation3Braak & Braak, Neuropathological staging of Alzheimer-related changes (1991)Open reference2.
Beyond phosphorylation, tau undergoes numerous other post-translational modifications that influence its aggregation and propagation properties. These include acetylation, ubiquitination, sumoylation, nitration, and truncation3Braak & Braak, Neuropathological staging of Alzheimer-related changes (1991)Open reference3. Tau acetylation at Lys280 (a site critical for aggregation) has been shown to facilitate tau aggregation and propagation, while preventing tau acetylation reduces pathology in mouse models3Braak & Braak, Neuropathological staging of Alzheimer-related changes (1991)Open reference4. Truncated tau fragments, particularly those generated by caspase cleavage, are more aggregation-prone and may serve as “seeds” that template the conversion of normal tau to pathological forms3Braak & Braak, Neuropathological staging of Alzheimer-related changes (1991)Open reference5.
Mechanisms of Tau Propagation
Intercellular Transfer
The propagation of tau between cells occurs through multiple mechanisms, including synaptic transmission, exosome secretion, and direct cellular uptake3Braak & Braak, Neuropathological staging of Alzheimer-related changes (1991)Open reference63Braak & Braak, Neuropathological staging of Alzheimer-related changes (1991)Open reference7. Synaptic activity has been shown to promote tau release from neurons, and tau can be detected in synaptic vesicles and presynaptic terminals3Braak & Braak, Neuropathological staging of Alzheimer-related changes (1991)Open reference8. The release of tau into the extracellular space appears to be a physiological process, as normal tau is secreted at low levels in vivo, but pathological forms are released at significantly higher rates3Braak & Braak, Neuropathological staging of Alzheimer-related changes (1991)Open reference9.
Once in the extracellular space, tau can be taken up by neighboring neurons through various endocytic mechanisms. Studies have demonstrated that tau can enter cells via clathrin-mediated endocytosis, macropinocytosis, and receptor-mediated pathways4In vivo tau PET imaging in Alzheimer's disease (2024)Open reference04In vivo tau PET imaging in Alzheimer's disease (2024)Open reference1. The uptake of extracellular tau is enhanced by its aggregation state, with oligomeric and fibrillar forms being internalized more efficiently than monomeric tau4In vivo tau PET imaging in Alzheimer's disease (2024)Open reference2. This suggests a positive feedback loop where cells taking up pathological tau develop pathology themselves and release even more tau, accelerating propagation.
Exosomal Secretion
Extracellular vesicles, particularly exosomes, represent another important pathway for tau propagation4In vivo tau PET imaging in Alzheimer's disease (2024)Open reference34In vivo tau PET imaging in Alzheimer's disease (2024)Open reference4. Exosomes are small vesicles (30-150 nm) released from cells that can contain various cellular proteins, including tau. Importantly, exosomal tau appears to be particularly efficient at inducing pathology in recipient cells, possibly because exosomes protect tau from degradation and concentrate aggregation-competent species4In vivo tau PET imaging in Alzheimer's disease (2024)Open reference5.
Studies have shown that exosomal tau is enriched in phosphorylated and aggregated forms compared to free extracellular tau4In vivo tau PET imaging in Alzheimer's disease (2024)Open reference6. Furthermore, exosomes can deliver tau directly to neurons and glia, and may also contribute to the inflammatory response by activating microglia4In vivo tau PET imaging in Alzheimer's disease (2024)Open reference7. The role of exosomes in tau propagation suggests that targeting exosome biogenesis or secretion could represent a therapeutic strategy for blocking tau spread.
Prion-Like Templated Conversion
The most mechanistically sophisticated model of tau propagation involves the templated conversion of normal tau to pathological conformers, analogous to prion protein propagation in prion diseases4In vivo tau PET imaging in Alzheimer's disease (2024)Open reference84In vivo tau PET imaging in Alzheimer's disease (2024)Open reference9. This model posits that pathological tau (“seed”) interacts with normal tau, inducing a conformational change that converts the normal protein to the pathological form. This converted tau can then template further conversions, creating a self-perpetuating cycle of pathology propagation5Tau and amyloid as predictors of cognitive decline (2023)Open reference0.
Evidence for prion-like templated conversion comes from multiple experimental systems. Studies using cell culture models show that treatment with brain-derived tau aggregates leads to intracellular aggregation of endogenous tau5Tau and amyloid as predictors of cognitive decline (2023)Open reference1. In mouse models, injection of brain homogenate containing pathological tau induces tau pathology in recipient animals, and this induced pathology can be transmitted to subsequent generations upon inoculation5Tau and amyloid as predictors of cognitive decline (2023)Open reference2. The strain-like properties of tau aggregates, where distinct conformations produce different disease phenotypes (e.g., AD vs. PSP), further support the prion-like model5Tau and amyloid as predictors of cognitive decline (2023)Open reference3.
Tau Strains and Selective Vulnerability
Strain Diversity
Emerging evidence indicates that tau aggregates exist in multiple conformational “strains” that are associated with different clinical and pathological phenotypes5Tau and amyloid as predictors of cognitive decline (2023)Open reference45Tau and amyloid as predictors of cognitive decline (2023)Open reference5. Like prion proteins, tau can adopt distinct aggregated conformations that are stable upon propagation and produce different disease characteristics. For example, the tau pathology in AD differs from that in PSP in terms of isoform composition (both 3R and 4R in AD, predominantly 4R in PSP), filament morphology (paired helical filaments in AD, straight filaments in PSP), and regional distribution5Tau and amyloid as predictors of cognitive decline (2023)Open reference6.
The strain hypothesis has important implications for understanding selective vulnerability in different tauopathies. Different brain regions may be preferentially affected by specific tau strains due to variations in local tau isoform expression, neuronal connectivity, or cellular factors that influence strain propagation5Tau and amyloid as predictors of cognitive decline (2023)Open reference7. Understanding the molecular basis of strain diversity could enable the development of strain-specific diagnostic and therapeutic approaches.
Regional Propagation Patterns
The propagation of tau follows characteristic anatomical patterns that have been well-characterized in both human postmortem studies and in vivo imaging studies using PET ligands that bind to tau aggregates5Tau and amyloid as predictors of cognitive decline (2023)Open reference85Tau and amyloid as predictors of cognitive decline (2023)Open reference9. The earliest tau pathology appears in the transentorhinal cortex and entorhinal cortex (Braak stages I-II), followed by the hippocampus and limbic structures (Braak stages III-IV), and finally the neocortex (Braak stages V-VI)6Relationship between tau pathology and cognition in Alzheimer's disease (2024)Open reference0. This progression correlates with the sequence of clinical symptoms, with episodic memory impairment appearing when hippocampal involvement occurs and cortical involvement corresponding to more severe cognitive deficits.
The propagation of tau along neural circuits suggests that connected neurons are particularly vulnerable to tau pathology6Relationship between tau pathology and cognition in Alzheimer's disease (2024)Open reference1. Studies using retrograde tracing in animal models have shown that neurons projecting to regions with existing tau pathology are more likely to develop tau pathology themselves, supporting a trans-synaptic spread model6Relationship between tau pathology and cognition in Alzheimer's disease (2024)Open reference2. This network-based propagation model has been validated in humans using resting-state functional connectivity MRI, which shows that patterns of tau deposition correlate with functional brain networks6Relationship between tau pathology and cognition in Alzheimer's disease (2024)Open reference3.
Therapeutic Implications
Targeting Tau Propagation
Understanding tau propagation mechanisms has revealed multiple potential therapeutic targets6Relationship between tau pathology and cognition in Alzheimer's disease (2024)Open reference46Relationship between tau pathology and cognition in Alzheimer's disease (2024)Open reference5. Strategies under investigation include: (1) blocking tau release through modulation of synaptic activity or exosome secretion; (2) preventing tau uptake by targeting cell surface receptors or endocytic pathways; (3) inhibiting templated conversion using small molecules that stabilize the normal tau conformation or interfere with protein-protein interactions required for seeding; (4) enhancing tau clearance through immunotherapy or autophagy induction6Relationship between tau pathology and cognition in Alzheimer's disease (2024)Open reference6.
Immunotherapeutic Approaches
Active and passive immunotherapy targeting tau has advanced to clinical trials, with several programs specifically designed to block tau propagation6Relationship between tau pathology and cognition in Alzheimer's disease (2024)Open reference76Relationship between tau pathology and cognition in Alzheimer's disease (2024)Open reference8. Anti-tau antibodies can neutralize extracellular tau and prevent its uptake by neurons, while also potentially facilitating clearance through Fc-mediated microglia activation. Early-phase clinical trials have demonstrated that anti-tau antibodies can reduce CSF tau levels, suggesting target engagement, though definitive evidence of clinical efficacy is still pending6Relationship between tau pathology and cognition in Alzheimer's disease (2024)Open reference9.
Small Molecule Inhibitors
Multiple small molecules targeting various aspects of tau pathology are in development7Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade (2010)Open reference07Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade (2010)Open reference1. Tau aggregation inhibitors aim to prevent the formation of pathological tau aggregates that can serve as seeds. Kinase inhibitors targeting GSK-3 beta or CDK5 could reduce pathological tau phosphorylation. Molecular chaperones and stabilizers aim to maintain normal tau function and prevent misfolding. While no disease-modifying tau-targeted therapy has yet reached clinical use, the pipeline remains active with multiple agents in various stages of development.
Conclusion
Tau propagation represents a central mechanism in the progression of Alzheimer’s disease and related tauopathies. The intercellular spread of pathological tau, driven by synaptic transmission, exosomal secretion, and prion-like templated conversion, explains the characteristic anatomical progression of tau pathology and its correlation with clinical disease progression. Understanding these mechanisms has revealed multiple therapeutic targets, and strategies to block tau propagation are actively being pursued. While significant challenges remain, the development of disease-modifying therapies targeting tau propagation offers hope for fundamentally altering the course of tauopathies.
See Also
External Links
References
- Tau propagation models and therapeutic implications (2024)
- Tau oligomers and propagation in neurodegenerative diseases (2023)
- Braak & Braak, Neuropathological staging of Alzheimer-related changes (1991)
- In vivo tau PET imaging in Alzheimer's disease (2024)
- Tau and amyloid as predictors of cognitive decline (2023)
- Relationship between tau pathology and cognition in Alzheimer's disease (2024)
- Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade (2010)
- Propagation of tau aggregation in a mouse model (2009)
- Cell-to-cell transmission of tau aggregates (2013)
- Tau physiology and pathology (2022)
- Mandelkow & Mandelkow, Tau in physiology and pathology (2012)
- Tau protein isoforms in Alzheimer's disease (2023)
- Wang & Mandelkow, Tau in physiology and disease (2016)
- Tau and microtubule dynamics (2023)
- Tau N-terminal domains in neuronal function (2024)
- Tau as a signaling molecule (2023)
- Stoothoff & Johnson, Tau phosphorylation (2005)
- Abnormal phosphorylation of tau in Alzheimer disease (1986)
- Tau and microtubule assembly (2023)
- Tau kinases and phosphatases (2023)
- GSK-3 beta in tau phosphorylation (2024)
- CDK5 and tau pathology in AD (2023)
- PP2A and tau dephosphorylation (2024)
- Tau post-translational modifications (2023)
- Tau acetylation and aggregation (2020)
- Caspase-cleaved tau in neurodegeneration (2023)
- Mechanisms of tau release (2023)
- Tau propagation mechanisms (2024)
- Activity-dependent tau release (2013)
- Extracellular tau in physiology and disease (2014)
- Tau uptake mechanisms (2017)
- Mechanisms of tau internalization (2019)
- Seed-competent tau oligomers (2018)
- Exosomal tau in tauopathy (2021)
- Tau exosomes and propagation (2024)
- Exosomal tau as efficient seeds (2017)
- Exosome-associated tau in AD (2023)
- Depletion of microglia reduces tau propagation (2015)
- Prion-like mechanisms in tauopathies (2024)
- Jucker & Walker, Self-propagation of protein aggregates (2013)
- Tau aggregation and seeding (2024)
- Guo & Lee, Cell models of tau propagation (2013)
- Induction of tau pathology in mice (2017)
- Distinct tau conformers in different tauopathies (2014)
- Tau strain diversity (2024)
- Tau strains and phenotypes (2023)
- Comparative pathology of tauopathies (2023)
- Regional vulnerability and tau strains (2023)
- Tau PET in Alzheimer's disease (2024)
- In vivo imaging of tau propagation (2023)
- Stages of tau pathology (2011)
- Network-based tau propagation (2024)
- Trans-synaptic tau spread (2022)
- Functional connectivity and tau spread (2020)
- Tau-based therapeutics (2024)
- Anti-tau therapy strategies (2023)
- Targets for tau-modifying therapies (2024)
- Anti-tau immunotherapy in AD (2024)
- Tau immunotherapy (2023)
- Mullard, Anti-tau antibody trials (2024)
- Tau-targeting small molecules (2023)
- Tau therapeutic pipeline (2024)
Sister wikis (recently updated · no domain on this page)
- Agent Recipe: AI-for-Biology Closed-Loop with Reviewer Handoffs and Eval Contracts
- Agent Recipe: AI-for-Biology Closed-Loop with Reviewer Handoffs and Eval Contracts
- test
- JGBO-I27: Top 10 GBO Questions for Prioritization
- JGBO-I27: Top 10 GBO Questions for Prioritization
- Design Brief: Beta-test Evaluation Protocol for SciDEX v2 Design Trajectories
- Andy — Showcase Findings (auto-curated)
- Kris — Showcase Findings (auto-curated)
Recent activity here
No recent events touching this page.